Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Other(1)

Detailed Status

Completed4

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

suspended120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

suspendedphase_2

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

NCT00790764

completedphase_2

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

NCT00548613

Clinical Trials (5)

Showing 5 of 5 trials

NCT00790764Phase 2

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

Suspended

NCT00721006Phase 2

Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Completed

NCT00643981Phase 1

Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia

Completed

NCT00518401Phase 1

Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Completed

NCT00548613Phase 1

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

Completed

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5